{
    "nctId": "NCT01132664",
    "briefTitle": "Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer",
    "officialTitle": "A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer, HER2+ Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 72,
    "primaryOutcomeMeasure": "Dose Limiting Toxicity (DLT) - Phase l Only",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* World Health Organization (WHO) Performance Status of \u2264 2\n* Patients with HER2+ breast cancer by local laboratory testing (immunohistochemistry \\[IHC\\] 3+ staining or fluorescence in situ hybridization \\[FISH\\] confirmation for IHC 2+ and 1+)\n* Documented tumor resistance to trastuzumab:\n\n  * Recurrence while on trastuzumab or within 12 months since the last infusion for patients who received trastuzumab as adjuvant treatment\n  * Progression while on or within 4 weeks since the last infusion of trastuzumab for patients who received trastuzumab for metastatic disease.\n* Documented evidence of progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) on trastuzumab-based therapy defined as:\n\n  * Phase Ib: at any time before study entry\n  * Phase II: within 16 weeks before date of first dosing\n* Received at least 1 but no more than 4 prior anit-HER2 based regimens including at least 1 regimen containing trastuzumab (adjuvant or neo-adjuvant trastuzumab will be considered as one prior regimen). HER2 directed therapies are defined as comprising trastuzumab, lapatinib, and trastuzumab-DM1 (T-DM1) only.\n\n  \u2022 Phase II only: trastuzumab, T-DM1 or lapatinib must be part of the most recent line of therapy\n* Previous lines of cytotoxic chemotherapy:\n\n  * Phase Ib: no more than 4 lines of cytotoxic chemotherapy\n  * Phase II: no more than 3 lines of cytotoxic chemotherapy\n\nMeasurable disease:\n\n* Phase Ib: patient has at least one measurable lesion or non-measurable disease as defined per RECIST\n* Phase II: patient has at least one measureable lesion as defined per RECIST\n\n\\|\\| Specific Inclusion Criteria for patients in BM cohorts:\n\n* Patient has evidence of progressing brain metastases and/or new metastatic brain lesion(s) without leptomeningeal disease.\n* Patient has received prior WBRT and/or SRS at at \\>28 and \\>/= 14 days, respectively, prior to starting study drug and the patient must have recovered from the side effects of the therapy\n* WHO performance status of \\</=1\n* PT INR \\</= 1.5\n* Any number of prior HER2-directed and cytotoxic regimens, and the most recent line may be any type of anti-neoplastic therapy\n\n\\|\\| Exclusion Criteria:\n\n* Patients with untreated brain metastases\n* Patients with acute or chronic liver, renal disease or pancreatitis\n* Patients with any peripheral neuropathy \u2265 Common Terminology Criteria for Adverse Events (CTCAE) grade 2\n* Patients with a history of mood disorders or \u2265 CTCAE grade 3 anxiety\n* Patient with clinical manifest diabetes mellitus or steroid-induced diabetes mellitus\n\n\\|\\| Specific Exclusion Criteria for patients in BM cohorts\n\n* Prior treatment with capecitabine\n* Patient has known dihydropyrimidine dehydrogenase (DPD) deficiency\n* Patient is currently receiving treatment with EIAED\n* Other protocol-defined inclusion/exclusion criteria may apply",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}